Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 133
Filter
Add more filters

Country/Region as subject
Publication year range
1.
J Intern Med ; 283(4): 380-391, 2018 04.
Article in English | MEDLINE | ID: mdl-29430747

ABSTRACT

AIMS: Left ventricular (LV) mechanics have been extensively investigated in heart failure with preserved ejection fraction (HFpEF) overshadowing for a long time the potential role of left atrium (LA) in that setting. Soluble suppression of tumorigenicity-2 receptor (ST2) is a novel biomarker of pro-fibrotic burden in HF. We hypothesized that due to the thinner LA wall, the fibrotic myocardial changes in HFpEF as indicated by elevated ST2 levels might more readily be reflected by impairments in the LA rather than the LV performance. METHODS AND RESULTS: In 86 patients with HFpEF, enrolled in the Karolinska Rennes (KaRen) biomarker prospective substudy, global LA strain (GL-LS) along with other echocardiographic as well as haemodynamic parameters and ST2 levels were measured. ST2 levels were inversely associated with LA-GS (r = -0.30, P = 0.009), but not with LA size, LV geometry, systolic or diastolic LV function (P > 0.05 for all). Furthermore, symptom severity correlated with ST2 and LA-GS, but not with LV structural or functional indices. Finally, during a median 18-month follow-up, LA-GS independently predicted the composite endpoint of HF hospitalization and all-cause mortality, even after adjustment for potential clinical and cardiac mechanical confounders, including LV global longitudinal strain and filling pressures (odds ratio: 4.15; confidence interval: 1.2-14, P = 0.023). CONCLUSIONS: Reduced LA-GS but not LV functional systolic and diastolic parameters were associated with the pro-fibrotic ST2 marker, HF symptoms and outcome in HFpEF.


Subject(s)
Heart Failure/physiopathology , Interleukin-1 Receptor-Like 1 Protein/metabolism , Ventricular Dysfunction, Left/physiopathology , Aged , Atrial Function, Left/physiology , Biomarkers/metabolism , Biomechanical Phenomena/physiology , Female , Heart Failure/blood , Humans , Male , Natriuretic Peptide, Brain/metabolism , Peptide Fragments/metabolism , Prospective Studies , Stroke Volume/physiology , Ventricular Dysfunction, Left/blood
2.
Europace ; 12(1): 71-7, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19864311

ABSTRACT

AIMS: Little is known about the incidence of paroxysmal atrial tachycardias (PAT) in patients with heart failure (HF). The availability of cardiac resynchronization therapy (CRT) devices with extended diagnostics for AT enables continuous monitoring of PAT episodes. The aim of the study was to assess the incidence over time of PAT in HF patients treated with CRT. METHODS AND RESULTS: Consecutive patients in NYHA functional class III or IV despite optimal drug therapy, QRS duration > or = 130 ms, left ventricular ejection fraction < or = 35%, and left ventricular end-diastolic dimension > or = 55 mm were eligible for enrolment. Patients with permanent or persistent atrial fibrillation (AF) were not included in the study. The first follow-up examination was performed 2 weeks after implantation, to optimize atrial sensing and CRT. Subsequent follow-up examinations were carried out 15 and 28 weeks after implantation, to collect the telemetric data. A total of 173 patients (67 +/- 11 years, M 116) were enrolled. Complete arrhythmia monitoring data were available from 120 patients over a mean follow-up of 183 +/- 23 days. Atrial tachycardia episodes were detected through telemetry in 25 of 120 patients (21%) during at least one follow-up examination. Atrial tachycardia episodes were recorded in 29 and 17% (P = NS) of patients with and without previous history of AF, respectively. CONCLUSION: More than 20% of the overall HF patient population treated with CRT suffer PAT episodes. Paroxysmal atrial tachycardia may interfere with response to CRT. Therefore, telemetric data may be relevant to drive the appropriate therapy in each patient.


Subject(s)
Atrial Fibrillation/epidemiology , Atrial Fibrillation/prevention & control , Cardiac Pacing, Artificial/statistics & numerical data , Electrocardiography, Ambulatory/statistics & numerical data , Heart Failure/epidemiology , Heart Failure/prevention & control , Aged , Atrial Fibrillation/diagnosis , Comorbidity , Europe/epidemiology , Female , Heart Failure/diagnosis , Humans , Incidence , Male , Risk Assessment/methods , Risk Factors , Treatment Outcome
3.
Arch Pediatr ; 16(4): 373-80, 2009 Apr.
Article in French | MEDLINE | ID: mdl-19217761

ABSTRACT

Congenital long QT syndrome (LQTS) is an inherited arrhythmia that can be sporadic or familial. It predisposes to sudden cardiac death by ventricular fibrillation, which can occur at any age, particularly in neonates. Recent postmortem molecular screening surveys have shown that 10 to 12% of sudden infant death syndrome (SIDS) cases were potentially related to congenital long QT syndrome. Current SIDS etiological surveys fail to diagnose LQTS. Specific questioning and electrocardiographic screening of first-degree relatives could greatly facilitate LQTS diagnosis. We propose adding these to screening modalities after a SIDS incident. Neonatal electrocardiographic screening could allow early identification of LQTS and adapted treatment and follow-up.


Subject(s)
Long QT Syndrome/complications , Sudden Infant Death/etiology , Electrocardiography , Genotype , Humans , Infant , Infant, Newborn , Long QT Syndrome/diagnosis , Long QT Syndrome/genetics , Neonatal Screening , Phenotype
6.
Ann Cardiol Angeiol (Paris) ; 56(5): 231-6, 2007 Nov.
Article in French | MEDLINE | ID: mdl-17854758

ABSTRACT

The beta-blocker (BB) prescription remains insufficient despite guidelines, especially, for chronic heart failure. Patients suffering chronic obstructive pulmonary disease (COPD) are particularly less treated by BB. The level of evidence for BB prescription is however especially high and as we will focus on, the level of evidence for the safety of BB in the COPD context is convincing enough. We, thus, propose to review the existing literature in regard to this prescription of BB in the chronic heart failure, in the coronary artery disease and for high blood pressure in COPD patients. We then propose our approach to improve the level of prescription of BB in COPD patient really justifying this prescription in cardiology.


Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Coronary Artery Disease/complications , Coronary Artery Disease/drug therapy , Heart Failure/complications , Heart Failure/drug therapy , Hypertension/complications , Hypertension/drug therapy , Pulmonary Disease, Chronic Obstructive/complications , Chronic Disease , Humans
7.
Ann Cardiol Angeiol (Paris) ; 56(6): 289-96, 2007 Dec.
Article in French | MEDLINE | ID: mdl-17963715

ABSTRACT

The ischemic mitral regurgitation is defined by a left ventricular muscle disease affecting the function of normal mitral valve leaflets. This kind of mitral regurgitation is founded in about 20% of the ischemic cardiomyopathy and is attributed to the remodelling of the left ventricular shape. Its development is associated to a significantly worse prognosis. Frequently this ischemic mitral regurgitation will be associated to episode of acute heart failure decompensation. Its diagnosis is sometimes challenging as the degree of regurgitation might be extremely variable and affected by loading conditions. Echocardiography and especially exercise stress echocardiography has been demonstrated as an extremely powerful tool for its diagnosis and the prognostic evaluation. Its treatment should include the pharmacological treatment of the chonic heart failure and we are still waiting data in regard to the prognostic role of surgical mitral valvuloplastie. Works are still ongoing.


Subject(s)
Echocardiography, Stress/methods , Mitral Valve Insufficiency/diagnostic imaging , Myocardial Ischemia/diagnostic imaging , Exercise Test , Heart Failure/etiology , Humans , Mitral Valve Insufficiency/therapy , Myocardial Ischemia/therapy , Prognosis , Ventricular Dysfunction, Left/diagnostic imaging , Ventricular Remodeling/physiology
9.
Arch Mal Coeur Vaiss ; 99(12): 1166-72, 2006 Dec.
Article in French | MEDLINE | ID: mdl-18942516

ABSTRACT

Cardiac resynchronisation therapy (CRT) is indicated in refractory cardiac failure with electrical asynchrony defined by QRS complexes > or =120 ms duration. The search for mechanical asynchrony is proposed for better selection of patients for CRT. Ischaemic and non-ischaemic cardiomyopathy do not necessarily show the same form of asynchrony. The authors studied the differences in correlation between electrical and mechanical asynchrony in these two patient populations. Fifty patients (34 dilated non-ischaemic and 16 ischaemic cardiomyopathy) in NYHA Classes III and IV, LVEF < 35%, consecutively implanted for CRT in 2004, were included. The trans-thoracic echocardiography, the ECG and clinical parameters (NYHA, 6 minute walk test, VO2 max) were compared. A non-significant improvement of the correlation between the aortic pre-ejection time and QRS duration was observed in the non-ischaemic group (r = 0.78, p< 0.0001) compared with the ischaemic cardiomyopathy group ( r = 0.56, p = 0.019). Similarly, intraventricular asynchrony seemed to be correlated with the duration of QRS in the non-ischaemic group (r = 0.65, p < 0.0001) unlike the ischaemic cardiomyopathy group (ns). Sub-group analysis of patients with QRS durations < 150 ms and > or =150 ms showed an electromechanical correlation irrespective of the QRS duration in the non-ischaemic group but this was only observed with the aortic pre-ejection time with QRS > or =150 ms in the ischaemic group. The authors conclude that there is a significant correlation between electrical and mechanical asynchrony in patients with non-ischaemic cardiomyopathy. This correlation only applies to intraventricular asynchrony with QRS durations > or =150 ms in the ischaemic group. A decision for CRT requires echocardiographic evaluation in ischaemic cardiomyopathy.


Subject(s)
Heart Failure/etiology , Heart Ventricles/physiopathology , Ventricular Dysfunction, Left/physiopathology , Aged , Cardiomyopathy, Dilated/diagnostic imaging , Cardiomyopathy, Dilated/physiopathology , Echocardiography, Transesophageal , Electrophysiology , Female , Heart Failure/diagnostic imaging , Heart Rate/physiology , Humans , Male , Regression Analysis , Ventricular Dysfunction, Left/diagnostic imaging
10.
Arch Mal Coeur Vaiss ; 99(6): 569-74, 2006 Jun.
Article in French | MEDLINE | ID: mdl-16878716

ABSTRACT

Between 30 and 50% of patients with rheumatoid arthritis (RA) have cardiac involvement but only 2 to 10% have clinical manifestations. The authors report the results of a retrospective study of 5 cases of aortic regurgitation (AR) requiring valve replacement. There were 4 women and 1 man with an average age of 48.4 years. The average duration of the RA was 19.6 years. All patients had cardiac failure. Aortic valve replacement was performed in all cases, with bioprostheses in 4 out of 5 patients. The histopathological examination of the valves showed a rheumatoid nodule in 3 cases and non-specific lesions in one case. In the fifth patient, rheumatoid serology was positive in the pericardial effusion. The average interval between the onset of symptoms and cardiac surgery was 3.6 months (range 1 to 6 months) There were 3 deaths at 3 days, 20 months and 10 years, two patients survive after 12 and 14 years. The characteristic rapid progression of this form of AR, which may be life-threatening, should be emphasised.


Subject(s)
Aortic Valve Insufficiency/surgery , Arthritis, Rheumatoid/complications , Heart Valve Prosthesis , Adult , Aortic Valve Insufficiency/complications , Aortic Valve Insufficiency/mortality , Arthritis, Rheumatoid/mortality , Bioprosthesis , Female , Humans , Male , Middle Aged , Retrospective Studies
11.
Arch Mal Coeur Vaiss ; 99(6): 579-84, 2006 Jun.
Article in French | MEDLINE | ID: mdl-16878718

ABSTRACT

A strategy combining percutaneous coronary angioplasty followed by valvular and/or coronary surgery was recently proposed as an alternative to the classical surgical only approach. The aim of this study was to assess the feasibility and the results of such a combined strategy with the two procedures performed the same day. The population comprised 34 patients including 17 with valvular disease and revascularisable coronary lesions (15 symptomatic severe aortic stenoses and two acute mitral insufficiencies) plus 17 multitrunk coronary patients without valvular disease but with an indication for revascularisation. Angioplasty was performed several hours prior to surgery and a loading dose of 300mg clopidogrel was administered immediately postoperatively; all patients were on aspirin before the procedure. The average age was 67 +/- 11 years, NYHA class 2.3 +/- 0.7, angina 73%, LVEF 58 +/- 10%. Single coronary artery disease was present in 26%, two vessel disease in 35% and three vessel disease in 39%. The success rate for angioplasty plus stent was 98%. 60 stents were active. Bypasses were exclusively arterial (left or right internal mammary arteries). We observed 4 in-hospital deaths, one of which was due to an infarct and three due to extra-cardiac causes (1 non-cardiogenic acute respiratory distress syndrome, 1 respiratory tract infection and 1 pyelonephritis). Further surgery was necessary in 4 cases: for haemorrhage and one episode of digestive tract haemorrhage. There were no additional deaths, coronary events nor haemorrhage at the end of an average follow-up of 15 +/- 6 months. The results of this combined strategy are encouraging in this population and merit further evaluation in a prospective study.


Subject(s)
Angioplasty, Balloon, Coronary/methods , Coronary Artery Disease/surgery , Heart Valve Diseases/surgery , Aged , Feasibility Studies , Female , Hospital Mortality , Humans , Male , Pilot Projects , Prospective Studies , Stents
12.
Clin Microbiol Infect ; 22(6): 572.e5-8, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27021424

ABSTRACT

Case series have suggested that pneumococcal endocarditis is a rare disease, mostly reported in patients with co-morbidities but no underlying valve disease, with a rapid progression to heart failure, and high mortality. We performed a case-control study of 28 patients with pneumococcal endocarditis (cases), and 56 patients with non-pneumococcal endocarditis (controls), not matched for sex and age, during the years 1991-2013, in one referral centre. Alcoholism (39.3% versus 10.7%; p <0.01), smoking (60.7% versus 21.4%; p <0.01), the absence of previously known valve disease (82.1% versus 60.7%; p 0.047), heart failure (64.3% versus 23.2%; p <0.01) and shock (53.6% versus 23.2%; p <0.01) were more common in pneumococcal than in non-pneumococcal endocarditis. Cardiac surgery was required in 64.3% of patients with pneumococcal endocarditis, much earlier than in patients with non-pneumococcal endocarditis (mean time from symptom onset, 14.1 ± 18.2 versus 69.0 ± 61.1 days). In-hospital mortality rates were similar (7.1% versus 12.5%). Streptococcus pneumoniae causes rapidly progressive endocarditis requiring life-saving early cardiac surgery in most cases.


Subject(s)
Endocarditis/pathology , Pneumococcal Infections/pathology , Streptococcus pneumoniae/isolation & purification , Adult , Aged , Aged, 80 and over , Cardiac Surgical Procedures , Case-Control Studies , Endocarditis/mortality , Endocarditis/surgery , Female , Hospitals , Humans , Male , Middle Aged , Pneumococcal Infections/mortality , Pneumococcal Infections/surgery , Prognosis , Survival Analysis , Treatment Outcome
13.
J Am Coll Cardiol ; 32(7): 1825-31, 1998 Dec.
Article in English | MEDLINE | ID: mdl-9857858

ABSTRACT

OBJECTIVES: The aim of this study was to assess the potential acute benefit of multisite cardiac pacing with optimized atrioventricular synchrony and simultaneous biventricular pacing in patients with drug-refractory congestive heart failure (CHF). BACKGROUND: Prognosis and quality of life in severe CHF are poor. Various nonpharmacological therapies have been evaluated but are restricted in their effectiveness and applications. In the early 1990s, dual chamber pacing (DDD) pacing was proposed as primary treatment of refractory CHF but results were controversial. Recently, tests to evaluate the effect of simultaneous pacing of both ventricles have elicited a significant improvement of cardiac performance. METHODS: Acute hemodynamic study was conducted in 18 patients with severe CHF (New York Heart Association class III and IV) and major intraventricular conduction block (IVCB) (QRS duration = 170+/-37 ms). Using a Swan-Ganz catheter, pulmonary artery pressure, pulmonary capillary wedge pressure (PCWP) and cardiac index (CI) were measured in different pacing configurations: atrial pacing (AAI) mode, used as reference, single-site right ventricular DDD pacing and biventricular pacing with the right ventricular lead placed either at the apex or at the outflow tract. RESULTS: The CI was significantly increased by biventricular pacing in comparison with AAI or right ventricular (RV). DDD pacing (2.7+/-0.7 vs. 2+/-0.5 and 2.4+/-0.6 l/min/m2, p < 0.001). The PCWP also decreased significantly during biventricular pacing, compared with AAI (22+/-8 vs. 27+/-9 mm Hg; p < 0.001). CONCLUSIONS: This acute hemodynamic study demonstrated that biventricular DDD pacing may significantly improve cardiac performance in patients with IVCB and with severe heart failure, in comparison with intrinsic conduction and single-site RV DDD pacing.


Subject(s)
Cardiac Pacing, Artificial/methods , Heart Failure/physiopathology , Heart Failure/therapy , Aged , Electrocardiography , Female , Hemodynamics , Humans , Male , Middle Aged
14.
Eur J Heart Fail ; 7(2): 205-14, 2005 Mar 02.
Article in English | MEDLINE | ID: mdl-15701468

ABSTRACT

BACKGROUND: Cardiac resynchronization therapy (CRT) is a promising new treatment for patients with heart failure and cardiac dyssynchrony. The CARE-HF study is a morbidity/mortality trial designed to provide conclusive evidence of the effects of CRT in patients with moderate to severe heart failure. METHODS: A description of the baseline characteristics of patients randomised in the CARE-HF trial. RESULTS: 813 Patients with predominantly NYHA class III (94%) heart failure were randomised in 82 centres. Their mean age was 65 (interquartile range [IQR] 59 to 72) years, 34% were aged >70 years and 27% were women. Thirty-eight percent of the patients had ischaemic heart disease. Mean heart rate was adequately controlled at 70 (IQR 60 to 78) bpm consistent with the use of beta-blockers. Supine systolic blood pressure was low at 117 (IQR 105 to 130) mm Hg. Eighty-eight percent of patients had a QRS > or =150 ms. Mean LV ejection fraction was 26% (IQR 22 to 29) and end-diastolic dimension was 7.2 (IQR 6.4 to 7.8) cm. Ninety-four percent of patients were receiving loop diuretics, 95% an ACE inhibitor or angiotensin receptor blocker (ARB), 72% a beta-blocker and 56% were taking spironolactone. CONCLUSIONS: The patients enrolled in CARE-HF had moderately severe heart failure and cardiac dysfunction with evidence of cardiac dyssynchrony. The population appears at high risk of events despite pharmacological therapy and therefore appropriate for a trial of CRT.


Subject(s)
Arrhythmias, Cardiac/therapy , Cardiac Pacing, Artificial , Heart Failure/therapy , Patient Selection , Ventricular Dysfunction, Left/therapy , Aged , Arrhythmias, Cardiac/complications , Arrhythmias, Cardiac/mortality , Atrioventricular Node , Female , Heart Failure/complications , Heart Failure/mortality , Humans , Male , Middle Aged , Multicenter Studies as Topic , Randomized Controlled Trials as Topic , Ventricular Dysfunction, Left/complications , Ventricular Dysfunction, Left/mortality
15.
Arch Mal Coeur Vaiss ; 98(2): 87-94, 2005 Feb.
Article in French | MEDLINE | ID: mdl-15787298

ABSTRACT

UNLABELLED: The prognosis of cardiac arrest outside hospital is directly related to the initial management. The aim of this work was to evaluate the characteristics of the initial and subsequent cardiological management of victims of cardiac arrest outside hospital with a retrospective analysis of data from the SAMU 35 (Emergency Medical Service, IIIe et Vilaine region) in the period April 1998 - April 2002. RESULTS: 533 non-traumatic cardiac arrests outside hospital were reported in 532 patients (average age 63 +/- 17, 73% male). The cardiac arrest occurred at home in 77% of cases. The initial cardiac rhythm documented was asystole in 63% of cases, ventricular fibrillation (VF) in 30% ventricular tachycardia (VT) in 1% and electromechanical dissociation in 6%. A cardiac aetiology was presumed in 294 (69%) of the 424 resuscitated patients. Among these, 22% (66/294) were admitted to coronary care units, 11% (31) left hospital alive, 8% (24) with no neurological sequelae. The survival rate for patients with cardiac arrest outside hospital in the presence of a witness and for whom the initial rhythm was VF or VT was 21%. The patient's age (<60 years)[OR: 1.05; CI 95%: 1.02-1.07; p < 0.001], rapid arrival of the SAMU (<10 min) [OR: 5.68; CI 95%: 1.42-22.7; p = 0.01] and resuscitation by the witness (OR: 8.26; CI 95%: 3.28-20.83; p < 0.001) were factors predictive of survival in a multivariate analysis. Coronary heart disease remains the principal cause of cardiac arrest in patients admitted to cardiology units (68%), with a recent coronary thrombosis shown in 40% of patients undergoing angiography (16/40). CONCLUSION: the prognosis of cardiac arrest outside hospital remains bleak, with a mortality of 90%. The survival rate is higher if the initial management is optimal, associated with bystander resuscitation and an immediate emergency service response allowing rapid defibrillation. Diagnosis and management of acute coronary syndrome in a cardiological setting must be integrated into the strategy.


Subject(s)
Heart Arrest/epidemiology , Heart Arrest/therapy , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Cardiopulmonary Resuscitation/statistics & numerical data , Coronary Angiography , Female , France/epidemiology , Heart Arrest/etiology , Hospitalization/statistics & numerical data , Humans , Male , Middle Aged , Retrospective Studies , Survival Rate , Tachycardia, Ventricular/epidemiology , Time Factors , Ventricular Fibrillation/epidemiology
16.
Arch Mal Coeur Vaiss ; 98(12): 1219-24, 2005 Dec.
Article in French | MEDLINE | ID: mdl-16435601

ABSTRACT

The symptom-limited exercise test is nowadays the gold standard to assess the exercise tolerance and the effects of different treatments in patients with chronic heart failure (CHF). A simpler alternative to this test is the 6-minute walk test. The 6-minute walk test is easy to realize and well-tolerated. Moreover, it is reliable just after one familiarization practice and requires standardization. Indeed, its conduction, which is submitted to some security precautions, can be altered by variation factors. The distance walked during the 6 minutes was the only parameter studied during the test. This parameter could allow judging the CHF severity and prognostic. The analyse of cardiorespiratory parameters has shown that the 6-minute walk test relative intensity is near to the peak individual values. Moreover, the cardiac and ventilatory adaptation of patient during this test depends to his own functional capacity. Lastly, the 6-minute walk test is a submaximal constant-load exercise, which should be performed in complement to the symptom-limited exercise test in cardiac patients.


Subject(s)
Exercise Test/methods , Heart Failure/diagnosis , Walking , Heart Failure/physiopathology , Humans , Physical Endurance , Predictive Value of Tests , Prognosis , Severity of Illness Index
17.
Arch Mal Coeur Vaiss ; 98(12): 1253-6, 2005 Dec.
Article in French | MEDLINE | ID: mdl-16435607

ABSTRACT

Thrombosis is the principal mechanism in vascular pathology, whether cerebral, coronary or peripheral. During the initial stages of infarction, coagulation contributes to vascular occlusion, the haemostatic factors playing a determining role in the development of atherothrombotic lesions. An increase in a coagulation protein, besides any lowering of anticoagulation protein levels, is a risk factor for thrombosis. Among these pro-coagulant factors, the pro-thrombogenic action of factor VIII has without doubt been studied the least. We report the case of a 62 year old patient with a personal and family history of many previous thrombotic episodes, both arterial and venous, in whom factor VIII hyperactivity was discovered after a myocardial infarction. This case underlines the association of the factor VIII complex with thrombosis, and its clinical repercussions, especially the incidence of coronary pathology.


Subject(s)
Coronary Thrombosis/metabolism , Factor VIII/metabolism , Venous Thrombosis/metabolism , Coronary Thrombosis/genetics , Factor VIII/genetics , Humans , Male , Middle Aged , Pedigree , Risk Factors , Smoking/adverse effects , Venous Thrombosis/genetics
18.
Am J Cardiol ; 84(12): 1417-21, 1999 Dec 15.
Article in English | MEDLINE | ID: mdl-10606115

ABSTRACT

Biventricular pacing has recently been proposed for treating patients with drug refractory heart failure and intraventricular conduction delay. The purpose is to restore ventricular relaxation and contraction sequences as homogeneously as possible. The aim of this study was to determine if some factors could predict the long-term clinical effectiveness of that new treatment. This study included 26 patients, aged 66 +/- 7 years, with drug refractory heart failure and wide QRS. Patients were implanted with a biventricular pacemaker. The left ventricle was paced through a coronary sinus tributary. New York Heart Association functional class, exercise tolerance, and left ventricular (LV) ejection fraction were collected at baseline and after pacemaker implantation. Patients were divided into 2 groups: group I = responders; group II = nonresponders. QRS duration and axis at baseline and during biventricular pacing, interventricular conduction time, and LV and right ventricular lead positions were compared between the 2 groups. Group I patients (n = 19) had a mean reduction of 1.3 in functional class and an increase in peak oxygen consumption rate by a mean of 50%. The only parameter that differed between the 2 groups was the QRS duration during biventricular pacing, with a significantly shorter value in group I than in group II (154 +/- 17 vs 177 +/- 26 ms; p = 0.016). Thus, a positive response to biventricular pacing is correlated with the quality of electrical resynchronization. The optimal positions of the right and LV leads would be those that could induce the greatest shortening of QRS duration.


Subject(s)
Electrocardiography , Heart Failure/therapy , Pacemaker, Artificial , Aged , Exercise Test , Female , Heart Conduction System/physiopathology , Heart Failure/physiopathology , Heart Ventricles/physiopathology , Humans , Male , Middle Aged , Myocardial Contraction/physiology , Oxygen Consumption/physiology , Stroke Volume/physiology , Treatment Outcome
19.
Eur J Heart Fail ; 3(4): 481-9, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11511435

ABSTRACT

BACKGROUND: Cardiac resynchronisation is a promising new intervention for patients with heart failure, left ventricular systolic dysfunction and ventricular dyssynchrony. OBJECTIVE: The CARE-HF trial is designed to evaluate the long-term effects of cardiac (atrio-bi-ventricular) resynchronisation on the mortality and morbidity of patients with heart failure due to left ventricular systolic dysfunction already receiving diuretics and optimal medical therapy with ACE inhibitors and beta-blockers (where indicated and tolerated). METHODS AND RESULTS: Approximately 800 patients will be randomised to device therapy or control and followed for a minimum of 18 months. A pragmatic study design has been chosen that does not attempt to conceal allocation from investigators or patients because it is impossible to guarantee maintenance of blinding for the duration of the study. The end-points committee will adjudicate events in a blinded fashion. Since cardiac resynchronisation may alter other aspects of the management of the patient, as would occur in clinical practice, the study should be considered a comparison of strategies rather than simply of a device. The primary end-point is all-cause mortality or unplanned cardiovascular hospitalisation. The study should complete recruitment during 2002 and report in 2004.


Subject(s)
Cause of Death , Heart Failure/mortality , Heart Failure/therapy , Heart-Assist Devices , Ventricular Dysfunction, Left/mortality , Ventricular Dysfunction, Left/therapy , Adrenergic beta-Antagonists/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Echocardiography , Electrocardiography , Female , Heart Failure/diagnosis , Humans , Male , Prognosis , Proportional Hazards Models , Reference Values , Sensitivity and Specificity , Severity of Illness Index , Survival Analysis , Treatment Outcome , United Kingdom , Ventricular Dysfunction, Left/diagnosis
20.
J Clin Pharmacol ; 29(12): 1089-96, 1989 Dec.
Article in English | MEDLINE | ID: mdl-2482304

ABSTRACT

Electrophysiological effects, antiarrhythmic activity and kinetics of levorotatory disopyramide (R(-) DP) and racemic disopyramide (equimolar mixture of R(-) DP and S(+) DP) were compared in patients with ventricular arrhythmias. This double blind cross-over randomized trial was achieved, at steady-state, following oral administration of 200 mg three times a day. In comparison with baseline values, electrophysiological data indicated that R(-) DP and racemic DP prolonged, significantly and similarly, PR interval (+11.7% and +10%, respectively, P less than .01), and QTc interval (+9.2% and +7%, respectively, P less than .001), while QRS interval was not significantly affected. The antiarrhythmic activity, assessed by percent reduction in ventricular extrasystoles frequency, showed a similar efficiency of levorotatory and racemic DP: 80% and 74%, respectively (P = .24). Ventricular tachycardias disappeared with both treatments in the three patients concerned. During the racemic period, the mean total plasma clearance, expressed as CL/F, of S(+) DP (114.6 ml/min), was significantly lower than that of R(-) DP (157 ml/min), (P less than .001). The mean total plasma clearance of R(-) DP, during the levorotatory period (163 ml/min), did not differ from the respective value determined during the racemic period (P = .32). During the racemic period, the stereoselective difference in total plasma clearances, which is not observed when DP enantiomers are administered separately, may result from an increase in unbound fraction of R(-) DP, due to the presence of S(+) DP, which is known to be a potent displacer of R(-) DP.


Subject(s)
Cardiac Complexes, Premature/drug therapy , Disopyramide/pharmacokinetics , Tachycardia/drug therapy , Administration, Oral , Adult , Aged , Cardiac Complexes, Premature/metabolism , Disopyramide/administration & dosage , Disopyramide/adverse effects , Double-Blind Method , Female , Heart Ventricles , Humans , Male , Middle Aged , Randomized Controlled Trials as Topic , Stereoisomerism , Tachycardia/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL